Skip to main content

Advertisement

SpringerLink
Log in

Immunologic therapy for secondary and primary progressive multiple sclerosis

  • Published:
Current Neurology and Neuroscience Reports Aims and scope Submit manuscript

Abstract

Multiple sclerosis (MS) is generally considered an immunemediated demyelinating disease, and treatments designed to modify the course of MS are immunosuppressive or immunomodulatory. Although most people with MS have a relapsing-remitting course initially, the majority will eventually experience a more gradual decline in neurologic function, termed secondary progressive MS. Some patients have gradual worsening from the beginning, termed primary progressive MS. Recent pathologic studies have revealed that axonal injury and neuronal degeneration are much more prominent in MS than previously recognized, and may be the explanation for the gradual decline in neurologic function that characterizes progressive MS. The results of several clinical trials in MS indicate that suppression of the immune-mediated inflammation may decrease the relapse rate in MS, but not stop the progressive loss of neurologic function. There are many promising approaches to this clinical dilemma, but none has been proven to be effective in stopping or retarding progressive MS. More well-designed, controlled, blinded, randomized clinical trials are needed to test these putative therapies. In the mean time, we should avoid subjecting patients to potentially dangerous and unproven regimens.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References and Recommended Reading

  1. Kilpatrick TJ, Soilu-Hänninen M: New treatments for multiple sclerosis. Aust NZ J Med 1999, 29:801–810.

    CAS  Google Scholar 

  2. Noseworthy JH, Gold R, Hartung HP: Treatment of multiple sclerosis: recent trials and future perspectives. Curr Opin Neurol 1999, 12:279–293.

    Article  PubMed  CAS  Google Scholar 

  3. Weinstock-Guttman B, Jacobs LD: What is new in the treatment of multiple sclerosis? Drugs 2000, 59:401–410.

    Article  PubMed  CAS  Google Scholar 

  4. Noseworthy JH, Lucchinetti C, Rodriguez M, Weinshenker BG: Multiple Sclerosis. N Engl J Med 2000, 343:938–952. An excellent review article covering etiopathology, diagnosis, and treatment of multiple sclerosis.

    Article  PubMed  CAS  Google Scholar 

  5. Lublin FD, Reingold SC: Defining the clinical course of multiple sclerosis: results of an international survey. Neurology 1996, 46:907–911.

    PubMed  CAS  Google Scholar 

  6. Kremenchutzky M, Cottrell D, Rice G, et al.: The natural history of multiple sclerosis: a geographically based study. 7. Progressive-relapsing and relapsing-progressive multiple sclerosis: a re-evaluation. Brain 1999, 122:1941–1949.

    Article  PubMed  Google Scholar 

  7. Thompson AJ, Montalban X, Barkhof F, et al.: Diagnostic criteria for primary progressive multiple sclerosis: a position paper. Ann Neurol 2000, 47:831–835.

    Article  PubMed  CAS  Google Scholar 

  8. European Study Group on Interferon b-1b in Secondary Progressive MS: Placebo-controlled multicentre randomised trial of interferon b-1b in treatment of secondary progressive multiple sclerosis. Lancet 1998, 352:1491–1497.

    Article  Google Scholar 

  9. Paty D: Results of the 3-year, double-blind, placebo-controlled study of interferon beta-1a (Rebif) in secondary progressive MS. Presented at the Ninth Annual Meeting of the European Neurological Society, Milan, Italy, June 5–9, 1999.

  10. Goodkin DE: North American Study Group on Interferon beta-1b in Secondary Progressive MS: Interferon beta-1b in secondary progressive MS: clinical and MRI results of a 3-year randomized controlled trial. Presented at the 52nd Annual Meeting of the American Academy of Neurology, San Diego, CA, May 1, 2000.

  11. Hughes R, for the SPECTRIMS Group: "Relapsing" versus "nonrelapsing" SPMS: different prognosis and response to interferon therapy in the SPECTRIMS study [abstract]. Neurology 2000, 54(suppl 3):A233.

    Google Scholar 

  12. McFarland HF: Comparative analysis of the outcome of two phase III studies of interferon beta-1b. Presented at the 52nd Annual Meeting of the American Academy of Neurology, San Diego, CA, May 1, 2000.

  13. Schwartz CE, Coulthard-Morris L, Cole B, Vollmer T: The quality-of-life effects of interferon beta-1b in multiple sclerosis. Arch Neurol 1997, 54:1475–1480.

    PubMed  CAS  Google Scholar 

  14. Nortvedt MW, Riise T, Myhr KM, et al.: Type I interferons and the quality of life multiple sclerosis patients. Results from a clinical trial on interferon alfa-2a. Mult Scler 1999, 5:317–322.

    PubMed  CAS  Google Scholar 

  15. Rice GP, Oger J, Duquette P, et al.: Treatment with interferon beta-1b improves quality of life in multiple sclerosis. Can J Neurol Sci 1999, 26:276–282.

    PubMed  CAS  Google Scholar 

  16. Rudick R, Antel J, Confavreux C, et al.: Recommendations from the National Multiple Sclerosis Society Clinical Outcomes Assessment Task Force. Ann Neurol 1997, 42:379–382.

    Article  PubMed  CAS  Google Scholar 

  17. Leary S: Positive MRI results from small trial of Avonex in primary progressive MS. Presented at the Sixteenth Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS), Toulouse, France, June 2000.

  18. Coles AJ, Wing MG, Molynuex P, et al.: Monoclonal antibody treatment exposes three mechanisms underlying the clinical course of multiple sclerosis. Ann Neurol 1999, 46:296–304. This was one of the first clinical trials to point out that a treatment may suppress the inflammatory component of multiple sclerosis (MS), but this may not translate into halting the progression of neurologic dysfunction in MS.

    Article  PubMed  CAS  Google Scholar 

  19. Rice GP, Filippi M, Comi G: Cladribine and progressive MS: clinical and MRI outcomes of a multicenter controlled trial. Neurology 2000, 54:1145–1155.

    PubMed  CAS  Google Scholar 

  20. Hartung HP, Gonsett R: Mitoxantrone in progressive multiple sclerosis (MS): a placebo-controlled, randomized, observer-blind European phase III multicenter study-clinical results. Mult Scler 1998, 4:325.

    Article  Google Scholar 

  21. Krapf H, Morrisey SP, Zenker O, et al.: Mitoxantrone in progressive multiple sclerosis (MS): a placebo-controlled, randomized, observer-blind European phase III multicenter study-MRI results. Mult Scler 1998, 4:380.

    Google Scholar 

  22. Fidler JM, DeJoy SQ, Gibbons JJ: Selective immunomodulation by the antineoplastic agent mitoxantrone. Suppression of B lymphocyte function. J Immunol 1996, 137:727–732.

    Google Scholar 

  23. Chaplain G, Milan C, Sgro C, et al.: Increased risk of acute leukemia after adjuvant chemotherapy for breast cancer: a population-based study. J Clin Oncol 2000, 18:2836–2842.

    PubMed  CAS  Google Scholar 

  24. Johnson KP, Brooks BR, Ford CC, et al. and the Copolymer 1 Multiple Sclerosis Study Group: Sustained clinical benefits of glatiramer acetate in relapsing multiple sclerosis patients observed for 6 years. Mult Scler 2000, 6:255–266. Using natural history data for comparison, this study demonstrates the sustained efficacy of glatiramer acetate in reducing the relapse rate and neurologic disability in patients with relapsing-remitting multiple sclerosis.

    PubMed  CAS  Google Scholar 

  25. Bornstein MB, Miller A, Slagle S, et al.: A placebo-controlled, double-blind, randomized, two-center, pilot trial of Cop 1 in chronic progressive multiple sclerosis. Neurology 1991, 41:533–539.

    PubMed  CAS  Google Scholar 

  26. La Mantia L, Eloi M, Salmaggi A, et al.: Cyclophosphamide in chronic progressive multiple sclerosis: a comparative study. Ital J Neurol Sci 1998, 19:32–36.

    Article  PubMed  Google Scholar 

  27. Hohol MJ, Olek MJ, Orav EJ, et al.: Treatment of progressive multiple sclerosis with pulse cyclophosphamide/methylprednisolone: response to therapy is linked to the duration of progressive disease. Mult Scler 1999, 5:403–409.

    PubMed  CAS  Google Scholar 

  28. Khan O, Zvartau-Hind M, Kamholz J, et al.: Efficacy and tolerability of monthly intravenous (i.v.) cyclophosphamide (CTX) in rapidly deteriorating MS patients resistant to conventional therapy [abstract]. Neurology 2000, 54(suppl 3):A337.

    Google Scholar 

  29. Myers LW, Ellison GW, Leake BD, Mickey MR: Selection of patients for therapeutic clinical trials in multiple sclerosis. In Frontiers in Multiple Sclerosis. Edited by Siva E, Kesselring J, Thompson AJ. London: Martin Dunitz; 1999:151–160.

    Google Scholar 

  30. Archelos JJ, Storch MK, Hartung HP: The role of B cells and autoantibodies in multiple sclerosis. Ann Neurol 2000, 47:694–706. This article reviews the potential importance of B cells and humoral immunity in the pathogenesis of multiple sclerosis.

    Article  PubMed  CAS  Google Scholar 

  31. Cross AH: MS: the return of the B cell. Neurology 2000, 54:1214–1215.

    PubMed  CAS  Google Scholar 

  32. Weinshenker BG, O’Brien PC, Petterson TM, et al.: A randomized trial of plasma exchange in acute central nervous system inflammatory demyelinating disease. Ann Neurol 1999, 46:878–886. This study demonstrates that plasma exchange leads to significant functional recovery in severely disabled patients following acute demyelinating events not responding to steroids.

    Article  PubMed  CAS  Google Scholar 

  33. Francis GS, Freedman MS, Antel JP: Failure of intravenous immunoglobin to arrest progression of multiple sclerosis: a clinical and MRI based study. Mult Scler 1997, 3:370–376.

    Article  PubMed  CAS  Google Scholar 

  34. Noseworthy JH, Weinshenker BG, O’Brien PC, et al.: Intravenous immunoglobin does not reverse recently acquired, apparently permanent weakness in multiple sclerosis [abstract]. Ann Neurol 1997, 42:A421.

    Google Scholar 

  35. Noseworthy JH, O’Brien PC, Petterson TM, et al.: Immunoglobulin administration does not reverse visual acuity loss in long-standing optic neuritis associated with multiple sclerosis [abstract]. Ann Neurol 1998, 44:A504.

    Google Scholar 

  36. Zang YC, Hong J, Tejeda-Simon MV, et al.: Th2 immune regulation induced by T cell vaccination in patients with multiple sclerosis. Eur J Immunol 2000, 30:908–913.

    Article  PubMed  CAS  Google Scholar 

  37. Hermans G, Medaer R, Raus J, Stinissen P: Myelin reactive T cells after T cell vaccination in multiple sclerosis: cytokine profile and depletion by additional immunizations. J Neuroimmunol 2000, 102:79–84. Pathologic T cells depleted by T-cell vaccination may recur in multiple sclerosis, but this study shows that they can be suppressed again with revaccination.

    Article  PubMed  CAS  Google Scholar 

  38. Correale J, Lund B, McMillan M, et al.: T cell vaccination in secondary progressive multiple sclerosis. J Neuroimmunol 2000, 107:130–139. This study shows that T cells reactive to several myelin antigens can be depleted by vaccination using T cells exposed to myelin.

    Article  PubMed  CAS  Google Scholar 

  39. Burt RK, Traynor AE, Pope R, et al.: Treatment of autoimmune disease by intense immunosuppressive conditioning and autologous hematopoietic stem cell transplatation. Blood 1998, 92:3605–3514.

    Google Scholar 

  40. Tyndall A, Fassas A, Passweg J, et al.: Autologous haematopoietic stem cell transplants for autoimmune disease-feasibility and transplant-related mortality. Bone Marrow Transplant 1999, 24:729–734. This interim report describes the outcome for hematopoietic stem cell transplants. The mortality rate has been higher than anticipated.

    Article  PubMed  CAS  Google Scholar 

  41. Openshaw H, Stuve O, Antel JP, et al.: Multiple sclerosis flares associated with recombinant granulocyte colony-stimulating factor. Neurology 2000, 54:2147–2150.

    PubMed  CAS  Google Scholar 

  42. Karussis D, Vourka-Karussis U, Mizrachi-Koll R, Abramsky O: Acute/relapsing experimental autoimmune encephalomyelitis: induction of long lasting, antigen-specific tolerance by sygeneic bone marrow transplantation. Mult Scler 1999, 5:17–21.

    PubMed  CAS  Google Scholar 

  43. Leiper AD: What is in store after stem-cell transplantation? Lancet 1999, 353:1544–1545.

    Article  PubMed  CAS  Google Scholar 

  44. Moreau T, Blanc S, Riche G, Confareux C: ERAZIMUS: Combination of azathioprine and beta-interferon in multiple sclerosis: results of a pilot safety study [abstract]. Mult Scler 1999, 5(suppl 1):S95.

    Google Scholar 

  45. Whartenby KA, Mills PC, Rogg J, et al.: An open label trial of combination MS therapy using IFN b1a and oral methotrexate 20 mg weekly [abstract]. Neurology 2000, 54(suppl 3):A24.

    Google Scholar 

  46. Lublin FD, Reingold SC: Combination therapy for treatment of multiple sclerosis. Ann Neurol 1998, 44:7–9.

    Article  PubMed  CAS  Google Scholar 

  47. Lucchinetti C, Brück W, Parisi J, et al.: Heterogeneity of multiple sclerosis lesions: implications for the pathogenesis of demyelination. Ann Neurol 2000, 47:707–717. Several reports from this group indicate that multiple sclerosis may be a clinical syndrome resulting from several different pathogenetic processes.

    Article  PubMed  CAS  Google Scholar 

  48. Trapp BD, Ransohoff RM, Fisher E, Rudick RA: Neurodegeneration in multiple sclerosis: relationship to neurological disability. Neuroscientist 1999, 5:48–57. An excellent review of the evidence that neuronal degeneration underlies the progressive neurologic disability of secondary progressive multiple sclerosis (MS) and primary progressive MS.

    Article  Google Scholar 

  49. Gonen O, Catalaa I, Babb JS, et al.: Total brain N-acetylaspartate: a new measure of disease load in MS. Neurology 2000, 54:15–19.

    PubMed  CAS  Google Scholar 

  50. Pitt D, Werner P, Raine CS: Glutamate excitotoxicity as a mechanism for axonal damage in multiple sclerosis [abstract]. Neurology 2000, 54(suppl 3):A258.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Multiple Sclerosis Research Center, University of California, Los Angeles, 710 Westwood Plaza, 90095-1769, Los Angeles, CA, USA

    Lawrence W. Myers MD

Authors
  1. Lawrence W. Myers MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Myers, L.W. Immunologic therapy for secondary and primary progressive multiple sclerosis. Curr Neurol Neurosci Rep 1, 286–293 (2001). https://doi.org/10.1007/s11910-001-0032-8

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11910-001-0032-8

Keywords

Search

Navigation